Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
{{output}}
Human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer (ABC) accounts for about 15-20% of all ABC cases. Large randomized trials have determined the standard first- and second-line treatments for this subgroup of patients, namely dual... ...
